Tapentadol is a centrally-acting synthetic analgesic with a dual mode of action as an agonist at the µ-opioid receptor and as a norepinephrine reuptake inhibitor. The drug is used to manage moderate to severe acute pain. It provides analgesia at similar levels of more potent narcotic analgesics such as hydrocodone, oxycodone, and meperidine with a more tolerable side effect profile.
Administration: Oral, round tablets available in 50, 75, and 100 mg strengths
Elimination: Tapentadol and its metabolites are excreted via the kidneys (99%). The terminal half-life is on average 4 hours. The major pathway of tapentadol metabolism is conjugation with glucuronic acid to produce glucuronides. A total of 3% of drug is excreted in urine as an unchanged drug. Tapentadol is additionally metabolized to n-desmethyl tapentadol (13%) by CYP2C9 and CYP2C19 and to hydroxy tapentadol (2%) by CYP2D6, which is further metabolized by conjugation.
Abuse Potential: Tapentadol can be abused in a manner similar to other opioid agonists, legal or illicit. It is generally abused by crushing, chewing, snorting, or injection. These practices pose a significant risk to the abuser that could result in overdose and death.
Storage Temp: 2-8°C
| Quantity | Each |
|---|---|
| Hazardous | No |
| Is Featured | No |
